{
  "id": "cluster_36_doc2",
  "content": "CoastalCare Partners issued updated coverage guidelines for erythropoiesis-stimulating agents effective April 2023. Under policy CG-ESA-9.2RS, biweekly darbepoetin alfa is now preferred for members with stage 3 CKD and iron deficiency anemia. The change follows efficiency reviews showing this regimen decreased average monthly costs by $1,240 per patient while maintaining outcomes. Providers must submit Serum Transferrin Receptor testing for prior authorization.",
  "metadata": {
    "format": "policy_document"
  }
}